Revvity Earnings Call Transcripts
Fiscal Year 2026
-
The Signals platform is expanding with AI-driven launches like BioDesign, LabGistics, and Xynthetica, aiming to accelerate research and shift to a consumption-based revenue model. Growth is expected in both software and reagents, with conservative guidance reflecting policy risks, especially in China.
-
Strong Q4 results and robust execution set the stage for 2026, with cost measures driving margin expansion and continued growth in diagnostics, software, and reproductive health. Signals software and new product launches are key to doubling revenue in five years.
-
The company has transformed into a focused life sciences and diagnostics leader, emphasizing innovation in software, reagents, and strategic partnerships. AI is expected to drive demand, while operational rigor supports margin expansion and strong cash flow. Guidance for 2026 is conservative, with upside potential if markets recover.
-
Management highlighted a successful transformation to a high-growth, high-margin life sciences and diagnostics company, driven by innovation, AI integration, and strategic partnerships. Operational improvements and disciplined capital allocation support strong margin and EPS growth targets for 2026 and beyond.
Fiscal Year 2025
-
Q4 and full-year 2025 results exceeded expectations, with strong diagnostics growth and robust share repurchases. 2026 guidance calls for 2%-3% organic growth, margin expansion, and continued innovation, while maintaining a prudent outlook amid market uncertainties.
-
Activity is increasing in life sciences and instrumentation, with software and AI initiatives driving strong growth. Immunodiagnostics and newborn screening are expanding, while China diagnostics stabilizes post-policy changes. Margin and revenue outlooks remain positive for 2026.
-
Q3 saw 1% organic growth, with Diagnostics outperforming and Life Sciences flat. Instrumentation demand is rebounding, software is up 25% YTD, and newborn screening continues strong growth. Margin expansion to 28% in 2025 is expected, despite China and tariff headwinds.
-
Q3 saw strong growth in software, newborn screening, and U.S. immunodiagnostics, with e-commerce and AI driving efficiency and innovation. The 2026 outlook targets 2–3% organic growth, margin expansion from mix and cost actions, and continued capital deployment through share repurchases and strategic M&A.
-
Q3 results met expectations with 1% organic growth, strong software and reproductive health performance, and adjusted EPS of $1.18. Full-year organic growth guidance is 2%-4%, with EPS guidance raised to $4.90-$5.00. DRG headwinds persist in China, but ex-China and software remain bright spots.
-
Q2 results were stable, with consumables and software showing growth, while instruments and China diagnostics faced headwinds. Strategic focus remains on software expansion, margin improvement, and selective M&A, with strong confidence in long-term prospects.
-
Q2 results were in line with expectations, but China diagnostics faced significant headwinds, leading to reduced full-year guidance. Life sciences software and reagents showed strong growth, while diagnostics and reproductive health are expected to drive a Q4 rebound. Margin expansion and robust free cash flow remain key strengths.
-
Q2 delivered 3% organic growth and $1.18 adjusted EPS, led by strong life sciences and software, but China diagnostics headwinds prompted a slight full-year guidance cut. Share repurchases reduced share count by 6% YoY, and innovation momentum remains strong.
-
Management highlighted a resilient, transformed portfolio with strong recurring revenue and margin expansion, despite macro headwinds. Growth is driven by diagnostics, software, and innovation, with share buybacks prioritized for capital allocation.
-
Solid Q1 performance was achieved through portfolio strength in diagnostics and software, effective tariff mitigation, and prudent guidance. Reagents outperformed peers, while instrumentation faced ongoing pressure. Capital allocation remains balanced, with BioLegend synergies supporting long-term growth.
-
Q1 2025 saw 4% organic growth and $1.01 adjusted EPS, exceeding expectations despite macro and tariff headwinds. Strong diagnostics and software performance offset academic softness, and full-year guidance for 3%-5% organic growth and $4.90-$5.00 EPS was reaffirmed.
-
The business has undergone a major transformation, with over 70% of revenue from new lines and a strong shift to recurring revenue. Software and diagnostics are growing steadily, with innovation and operational synergies driving margin expansion. Growth in China and new product launches support a positive outlook.
-
The event highlighted ongoing portfolio transformation, geographic diversification, and prudent growth guidance. Specialized products, operational efficiency, and innovation in reagents, diagnostics, and software are driving resilience and margin expansion.
-
A multi-year transformation has positioned the business for growth in high-value, differentiated markets, with resilient supply chains and prudent guidance amid macro uncertainty. Innovation and margin expansion remain key priorities, supported by ongoing M&A and strategic partnerships.
-
Revvity has transformed its business, focusing on high-growth Life Sciences and Diagnostics with strong recurring revenue and expanding margins. 2025 guidance projects 3%-5% organic growth and continued margin expansion, with resilience driven by innovation, specialized markets, and strategic capital allocation.
-
Revvity has transformed into a focused life sciences and diagnostics company, achieving strong recurring revenue and organic growth. The company expects gradual market normalization in 2025, continued innovation, and a balanced capital allocation strategy, with resilience in key markets like China.
Fiscal Year 2024
-
Q4 2024 delivered 6% organic growth and 30%+ adjusted margins, with strong cash flow and EPS above guidance. 2025 outlook calls for 3%-5% organic growth, margin expansion, and continued investment, while maintaining a prudent stance amid macro uncertainties.
-
Reagent and software sales are driving growth and margin improvement, with stabilization in CapEx and positive trends in pharma biotech. China remains a mid-single-digit growth market, and innovation in diagnostics and newborn screening supports future expansion.
-
The company has transformed into a high-growth, innovation-driven life sciences and diagnostics leader, with 80% recurring revenue and robust financials. Growth is fueled by portfolio realignment, new product innovation, and operational synergies, supporting 6%-8% organic growth and expanding margins.
-
Q3 results exceeded expectations with strong cash flow, margin expansion, and robust diagnostics and software performance. Full-year organic growth outlook was revised down to 0%-1% due to slower instrument recovery, but EPS guidance was raised. Shareholder returns remain a priority.
-
Revvity, following major portfolio transformation, expects 2% organic growth in 2024, outperforming peers amid industry pressures. Margin expansion is driven by operational efficiencies, with diagnostics and software segments showing strong growth. Capital allocation is shifting to share repurchases as M&A slows.
-
Organic growth continues to outpace peers, supported by a differentiated portfolio and strong execution. China remains resilient, software and immunodiagnostics drive segment growth, and capital deployment shifts to buybacks amid robust free cash flow.
-
Q2 2024 results exceeded expectations with strong margins, cash flow, and outperformance in diagnostics and software offsetting pharma/biotech headwinds. Full-year EPS and margin guidance were raised, and share repurchases will accelerate given robust cash generation and a healthy balance sheet.
-
Performance exceeded expectations with stable market conditions and no major demand uptick. Portfolio transformation has driven recurring revenue and margin expansion, with strong growth opportunities in diagnostics, software, and underpenetrated regions. Margin targets remain ambitious, supported by cost controls and synergies.